Literature DB >> 26008812

LRRK2 Pathways Leading to Neurodegeneration.

Mark R Cookson1.   

Abstract

Mutations in LRRK2 are associated with inherited Parkinson's disease (PD) in a large number of families, and the genetic locus containing the LRRK2 gene contains a risk factor for sporadic PD. The LRRK2 protein contains several domains that suggest a role in cellular signaling, including a kinase domain. It is also clear that LRRK2 interacts, either physically or genetically, with several other important proteins implicated in PD, suggesting that LRRK2 may be a central player in the pathways that underlie parkinsonism. As such, LRRK2 has been proposed to be a plausible target for therapeutic intervention, with kinase inhibition being pursued most actively. However, there are still several fundamental aspects of LRRK2 biology and function that remain unresolved at this time. This review will focus on the key questions of normal function of LRRK2 and how this might be related to the pathophysiology of PD.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26008812      PMCID: PMC5839465          DOI: 10.1007/s11910-015-0564-y

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  100 in total

Review 1.  Rab proteins as membrane organizers.

Authors:  M Zerial; H McBride
Journal:  Nat Rev Mol Cell Biol       Date:  2001-02       Impact factor: 94.444

Review 2.  Multiple roles of auxilin and hsc70 in clathrin-mediated endocytosis.

Authors:  Evan Eisenberg; Lois E Greene
Journal:  Traffic       Date:  2007-05-04       Impact factor: 6.215

3.  Sucrose-induced vacuolation results in increased expression of cholesterol biosynthesis and lysosomal genes.

Authors:  Amanda Helip-Wooley; Jess G Thoene
Journal:  Exp Cell Res       Date:  2004-01-01       Impact factor: 3.905

Review 4.  The Roco protein family: a functional perspective.

Authors:  Ignacio Marín; Wouter N van Egmond; Peter J M van Haastert
Journal:  FASEB J       Date:  2008-06-03       Impact factor: 5.191

5.  Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease.

Authors:  Byoung Dae Lee; Joo-Ho Shin; Jackalina VanKampen; Leonard Petrucelli; Andrew B West; Han Seok Ko; Yun-Il Lee; Kathleen A Maguire-Zeiss; William J Bowers; Howard J Federoff; Valina L Dawson; Ted M Dawson
Journal:  Nat Med       Date:  2010-08-22       Impact factor: 53.440

6.  LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice.

Authors:  Martin C Herzig; Carine Kolly; Elke Persohn; Diethilde Theil; Tatjana Schweizer; Thomas Hafner; Christine Stemmelen; Thomas J Troxler; Peter Schmid; Simone Danner; Christian R Schnell; Matthias Mueller; Bernd Kinzel; Armelle Grevot; Federico Bolognani; Martina Stirn; Rainer R Kuhn; Klemens Kaupmann; P Herman van der Putten; Giorgio Rovelli; Derya R Shimshek
Journal:  Hum Mol Genet       Date:  2011-08-09       Impact factor: 6.150

7.  GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1.

Authors:  Klodjan Stafa; Alzbeta Trancikova; Philip J Webber; Liliane Glauser; Andrew B West; Darren J Moore
Journal:  PLoS Genet       Date:  2012-02-09       Impact factor: 5.917

Review 8.  Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?

Authors:  Iakov N Rudenko; Ruth Chia; Mark R Cookson
Journal:  BMC Med       Date:  2012-02-23       Impact factor: 8.775

9.  Biochemical characterization of highly purified leucine-rich repeat kinases 1 and 2 demonstrates formation of homodimers.

Authors:  Laura Civiero; Renée Vancraenenbroeck; Elisa Belluzzi; Alexandra Beilina; Evy Lobbestael; Lauran Reyniers; Fangye Gao; Ivan Micetic; Marc De Maeyer; Luigi Bubacco; Veerle Baekelandt; Mark R Cookson; Elisa Greggio; Jean-Marc Taymans
Journal:  PLoS One       Date:  2012-08-29       Impact factor: 3.240

Review 10.  Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions.

Authors:  Elisa Greggio; Mark R Cookson
Journal:  ASN Neuro       Date:  2009-04-14       Impact factor: 4.146

View more
  53 in total

1.  Kinase inhibition of G2019S-LRRK2 enhances autolysosome formation and function to reduce endogenous alpha-synuclein intracellular inclusions.

Authors:  Julia Obergasteiger; Giulia Frapporti; Giulia Lamonaca; Sara Pizzi; Anne Picard; Alexandros A Lavdas; Francesca Pischedda; Giovanni Piccoli; Sabine Hilfiker; Evy Lobbestael; Veerle Baekelandt; Andrew A Hicks; Corrado Corti; Peter P Pramstaller; Mattia Volta
Journal:  Cell Death Discov       Date:  2020-06-08

Review 2.  Selective neuronal vulnerability in Parkinson disease.

Authors:  D James Surmeier; José A Obeso; Glenda M Halliday
Journal:  Nat Rev Neurosci       Date:  2017-01-20       Impact factor: 34.870

3.  LRRK2 Is Associated with Recurrence-Free Survival in Intrahepatic Cholangiocarcinoma and Downregulation of LRRK2 Suppresses Tumor Progress In Vitro.

Authors:  Shen Gu; Jun Chen; Qun Zhou; Minghao Yan; Jian He; Xiaodong Han; Yudong Qiu
Journal:  Dig Dis Sci       Date:  2019-09-05       Impact factor: 3.199

Review 4.  LRRK2 links genetic and sporadic Parkinson's disease.

Authors:  Jillian H Kluss; Adamantios Mamais; Mark R Cookson
Journal:  Biochem Soc Trans       Date:  2019-03-05       Impact factor: 5.407

Review 5.  Models of LRRK2-Associated Parkinson's Disease.

Authors:  Yulan Xiong; Ted M Dawson; Valina L Dawson
Journal:  Adv Neurobiol       Date:  2017

Review 6.  Microglia and astrocyte dysfunction in parkinson's disease.

Authors:  Tae-In Kam; Jared T Hinkle; Ted M Dawson; Valina L Dawson
Journal:  Neurobiol Dis       Date:  2020-07-28       Impact factor: 5.996

Review 7.  The function of orthologues of the human Parkinson's disease gene LRRK2 across species: implications for disease modelling in preclinical research.

Authors:  Rebekah G Langston; Iakov N Rudenko; Mark R Cookson
Journal:  Biochem J       Date:  2016-02-01       Impact factor: 3.857

Review 8.  Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease.

Authors:  Andrew B West
Journal:  Exp Neurol       Date:  2017-07-29       Impact factor: 5.330

Review 9.  New Frontiers in Parkinson's Disease: From Genetics to the Clinic.

Authors:  Lamya S Shihabuddin; Patrik Brundin; J Timothy Greenamyre; Diane Stephenson; S Pablo Sardi
Journal:  J Neurosci       Date:  2018-10-31       Impact factor: 6.167

10.  Age-Dependent Dopaminergic Neurodegeneration and Impairment of the Autophagy-Lysosomal Pathway in LRRK-Deficient Mice.

Authors:  Emilie Giaime; Youren Tong; Lisa K Wagner; Yang Yuan; Guodong Huang; Jie Shen
Journal:  Neuron       Date:  2017-10-19       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.